• Metadoro
  • Products
  • News and analysis

News and analysis

Check market insights shared by our community members
14.01.2025
Merck Becomes Interesting to Be Added to a Portfolio

Merck & Co (MRK) stocks have shown signs of becoming a compelling buy opportunity. Over the past six months, the stock has been in a downtrend, declining 29.8% to $94.50 per share. However, since mid-November, MRK has demonstrated a reversal of momentum, rebounding by 10.0% to reach $104.87 on December 5. Following a brief pullback and consolidation period, the stock has retested the downtrend resistance and appears poised to continue its upward trajectory.

With prices currently positioned to target $110.00, this represents a potential 9-10% upside from the present levels. Setting a stop-loss at $93.50 aligns with a prudent risk management strategy, providing protection against further downside while allowing for upside potential. The recent consolidation phase further supports the case for a breakout, making this an attractive moment to consider initiating or adding to a position in MRK.

14.01.2025
Tezos Is Seen Hodling above $1.200

Tezos (XTZ) has declined slightly by 0.2% this week, trading at $1.249, following Bitcoin’s (BTC) drop to $89,158, which triggered widespread altcoin sell-offs due to concerns of a potential further decline in BTC to $80,000. However, Bitcoin managed to hold above the critical support level at $89,000-$91,000, offering some relief to the broader crypto market.

Speculation about a shift in U.S. trade policy has provided additional support to crypto assets. Reports suggest the new U.S. administration may pursue a gradual increase in tariffs rather than an abrupt hike, which could help alleviate inflationary pressures and lead to a less aggressive monetary stance from the Federal Reserve.

This development is a positive signal for the cryptocurrency market and may help Tezos maintain its position above the key support level of $1.200.

16.01.2025
Delta Is Taking Off To Update Its Highs

Delta Air Lines stock rose markedly by low double digits in the first ten days of the new year. The U.S. carrier has served more than 200 million customers in 2024, when it was also recognized by J.D. Power, a leading American data analytics and consumer intelligence company, for being No. 1 in First/Business and Premium Economy Passenger Satisfaction. Travelers became more willing to spend extra money for swanky seats when meeting a high level of service. Delta is just positioning itself as the nation's premium airline. And what's more important, its Christmas quarter's earnings reportedly surpassed average analyst pool projections. Driven by stronger travel demand, smart financial management and capacity discipline, Delta business provided last three-months' profit of $1.85 per share vs $1.28 at the same period one year ago, compared to $1.75 in consensus estimates. On January 10, the airline industry leader put its future profit levels within a range between $0.70 and $1 per share in the current quarter through the end of March, while analyst expectations were focused on $0.77 cents, according to data compiled by LSEG. The starting months of each year always perform worse. It is clear that all carriers made losses in the Covid years of 2020-2022, but Delta profits only recovered into a range from $0.25 to $0.45 in the first quarter of 2023 and 2024, respectively, but Q1 profit numbers varied from $0.75 to $0.96 even in the three blessed years before the pandemic. Delta added that it is forecasting annual earnings in excess of $7.35 a share, which would be the highest in its 100-year history, based on its planned revenue growth of 7% to 9% in the March quarter from a year ago. The announcement could be compared to an adjusted profit of $6.16 a share in 2024. The company happily breaks through ticket prices' rising effects, almost undisturbed by a reduction in airline seats in the domestic market, which was peculiar for most carriers. Thus, new expectations created a fertile ground for setting new price records, even though price movements on Delta charts look most convincing among its other American rivals.

By the way, Citigroup analysts freshly updated their outlook on Delta Air Lines shares to raise their price target to $80 from the previous $77, vs the actual range around $65 per share where the stock just came after a reasonable market correction from last week's and all-time highs. Citigroup said it has included factors like higher revenue per available seat mile, projections of slightly lower fuel prices, increased taxation, a minor rise in share count, and the incorporation of fourth-quarter 2024 results into their financial model, which has projected Delta's profit at $7.49 per share in 2024 and $8.72 in 2025. Delta shares are Buy-rated at Citi, and we agree with their positive estimates in general, while keeping in mind even better price goals somewhere between $82.5 and $85.

23.01.2025
Ontology Is Sliding Towards $0.2000

Ontology (ONT) is down 2.3% this week, trading at $0.2176, in line with the broader crypto market where Bitcoin (BTC) has declined 2.0% to $101,632. While the new U.S. administration has made some strides toward fairer crypto regulation, Donald Trump has remained silent on the highly anticipated issue of adding Bitcoin to U.S. federal reserves.

Market speculation is rampant, with figures like BlackRock CEO Larry Fink suggesting Bitcoin could surge to $700,000 per coin if sovereign wealth funds begin accumulating. Other forecasts predict Bitcoin reaching $250,000 by year-end. While such projections could foster optimism, the lack of decisive action or announcements regarding U.S. crypto reserves is weighing heavily on the market.

For Ontology, the situation remains bearish. Having breached the critical support at $0.2500 last week, the token is now approaching the $0.2000 level. A failure to provide clear evidence or statements about U.S. federal crypto reserve plans could see ONT fall even further, breaching the $0.2000 mark and deepening its losses.

09.01.2025
VeChain Is Suffering on Rising Borrowing Costs

VeChain (VET) has fallen 12.7% this week, trading at $0.0445, underperforming the broader cryptocurrency market. Bitcoin (BTC), the leading cryptocurrency, has declined by 5.6% to $93,220, with bearish momentum building as it approaches key support at $89,000-$91,000. This decline is largely attributed to tightening monetary conditions in the United States, which continue to weigh on risk assets. Investor confidence is further shaken by significant net outflows from spot BTC-ETFs, which lost $583 million on Wednesday, marking the second-largest single-day outflow on record.

If BTC falls below the critical support level of $89,000-$91,000, VeChain is likely to extend its losses, with prices potentially declining another 10% to $0.0400. A sustained drop in BTC could push VET even lower, towards $0.0300. Conversely, a strong rebound in BTC prices to the $100,000 level could drive VET back up to $0.0500, representing a recovery of approximately 12% from current levels.

The Best-Looking Biotech Stock

After three weeks of a severe technical retracement from an all-time high at $966 on July 15 to fresh dips below $750 in early August, Eli Lilly revealed itself once again as the most attractive company for mass. The company's new and popular weight loss treatment Mounjaro statistically results in a more remarkable growing thin effect than rivals' obesity drugs, in a real-world comparison across other benchmarks, including Novo Nordisk's obesity drug named Wegovy or Ozempic, which are actually two different brand names for the same injectable drug, semaglutide, AMA Internal Medicine journal reported about a month ago. Patients taking Mounjaro were 76% more likely to lose at least 5% of their body weight, more than twice as likely to lose at least 10%, and more than three times as likely to lose at least 15%, compared to patients taking the second place drug, researchers found after analysing weight loss trajectories in 9,193 patients. Mounjaro sales reached $3.1 billion, with best growth pace in the UK, UAE and Saudi Arabia markets, and now Eli Lilly additionally reports robust, and better than expected, financial growth.

Its quarterly EPS (equity per share) just came out at $3.92 on $11.3 billion of total sales vs nearly $2.75 per share on about $10 billion in consensus estimates, and also against $2.54 per share on $8.77 billion in the previously record quarter, meaning a 42.5% QoQ and a 85.2% YoY surplus in EPS. What a wonderful margin performance in a very challenging environment! Eli Lilly's CEOs revised their annual revenue outlook upwards to forecast it between $45.4 billion and $46.6 billion for 2024, following a 36% increase in revenue YoY so far and "with operating margins in the mid- to high-30s range". Revenue in Europe added 20% in constant currency, 15% in Japan and 61% in the "rest of the world" (outside the US. and the EU).

Eli Lilly's share price quickly soared to $875 to $905 resistance area before the weekend, while a rather sceptical Deutsche Bank immediately upgraded the stock from Hold to Buy with a 15% of additional upside potential to $1,025 at least and BMO Capital Markets provided its rosy path assessment with a new price target at $1,101 from $1,001. Even average expert poll projections are shifted to a $4.28 of EPS at nearly $12 billion of sales for Q3. And so, we do agree with a more optimistic outlook, feeling that the most prominent manufacturing expansion in the biopharma industry since the pandemic time should be given not only a praise but also monetary rewards. Its current supply capacity is 1.5 times above the level which was measured only 1.5 ago.

The company continues to invest heavily in its manufacturing and expansion, with over $18 billion committed to facilities and announced plans to put an extra $5.3 billion in its manufacturing sites in Indiana. It is ready to acquire Morphic Therapeutic as well to better withstand chronic diseases. It achieved "the approval of Kisunla, the brand name for donanemab in the US for the treatment of Alzheimer's disease, the approval of Jaypirca in Japan for people with relapsed or refractory mantle cell lymphoma, the submission of tirzepatide in the U.S. and the EU for the treatment of moderate to severe obstructive sleep apnoea in adults with obesity and the positive top line results from the SUMMIT Phase 3 trial evaluating tirzepatide in adults with heart failure with preserved injection fraction and obesity", according to last earnings call's materials. This is an impressive list of achievements to generate both more healthy life profits. Besides, Eli Lilly raises its dividend payment for 9 consecutive years. It now equals to $1.3 per share, maybe not much compared to the stock's price growth but is also a pleasant indication of the company's self-confidence.

3041
Rafael Quintana Martinez
Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/
The Yen Is Set to Become Weaker

USDJPY experienced a significant decline of 5.5% in August, dropping to 141.67, the lowest level since January 3. The pair then rebounded by 4.3% to 147.89, reflecting substantial volatility for a major reserve currency. In comparison, no other reserve currency has shown such extreme movement; for instance, the Mexican peso, which is not a reserve currency, dropped by 14.8%.

This sharp decline left USDJPY rapidly oversold, with the price falling below the uptrend support established since January 16, 2023. Such an oversold condition suggests a strong potential for recovery. Even if the pair experiences further minor declines, there is limited room for additional downside. The oversold tension makes a recovery likely, making it reasonable to consider buying in the 144.00-146.00 range. The targets for this potential rebound are set at 150.0-152.00, with a stop-loss recommended at 140.00.

3051
Rafael Quintana Martinez
Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/
Bitcoin is Recovering Towards $70,000

Bitcoin (BTC) has gained 4.5% this week, reaching $61,018 and effectively erasing the 16.0% losses it experienced on Monday—an impressive recovery. The cryptocurrency briefly surged to $62,726 on early Friday, surpassing its pre-sell-off peak from before the downturn in risky assets began on August 2.

This strong rebound was bolstered by a ruling from Judge Analisa Torres, who ordered Ripple to pay a $125 million fine after four years of litigation with the U.S. Securities and Exchange Commission (SEC). The fine is significantly lower—16 times less—than what the SEC had initially demanded. Ripple's price surged by 25.0% to $0.6424 on the news.

Further supporting Bitcoin and other risky assets was positive news from the U.S. labor market. The tech-heavy Nasdaq 100 index jumped by 4.2% on August 8, helping to push Bitcoin above $60,000. With this momentum, Bitcoin appears poised to potentially rise toward the $70,000 mark.

3576
Rafael Quintana Martinez
Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/
Cardano Seems to Increase Its Upside Momentum

Cardano (ADA) has seen a relatively modest decline of 3.5% this week, trading at $0.3330, a strong recovery considering its sharp 20% drop on Monday when prices hit a low of $0.2749, the lowest since October 23, 2023. This recovery is in line with the general market trend, as Bitcoin (BTC) also pared down its earlier 16% decline to just 1.5%, now hovering around $57,350.

However, investor sentiment around Cardano is mixed due to concerns over declining activity on its network. Interestingly, retail investor activity has surged as prices dipped to around $0.3000, helping to drive a rebound. Cardano prices have since bounced off the $0.3000 support level and are now trending toward $0.4000, with potential for further growth.

The upcoming Chang hard fork is expected to further bolster this upward momentum, providing additional support for Cardano’s price recovery.

2752
106

Join our community

Share your professional and amateur observations, exchange experiences, anticipate developments

Category
All
Stocks
Crypto
Etf
Commodities
Indices
Currencies
Energies
Metals
Instruments
Author
All
Metadoro
Contributors